Squarepoint Ops LLC Raises Stock Position in Twist Bioscience Corporation $TWST

by · The Markets Daily

Squarepoint Ops LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 192.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,708 shares of the company’s stock after buying an additional 47,221 shares during the period. Squarepoint Ops LLC owned about 0.12% of Twist Bioscience worth $2,638,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after purchasing an additional 1,588,587 shares during the period. Strs Ohio purchased a new stake in Twist Bioscience during the 1st quarter valued at $711,000. Hsbc Holdings PLC bought a new stake in Twist Bioscience in the first quarter worth $228,000. Jacobs Levy Equity Management Inc. purchased a new position in Twist Bioscience during the first quarter worth $1,662,000. Finally, Conestoga Capital Advisors LLC purchased a new position in Twist Bioscience during the second quarter worth $1,044,000.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 4,887 shares of Twist Bioscience stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $156,774.96. Following the completion of the sale, the chief executive officer directly owned 733,922 shares in the company, valued at $23,544,217.76. The trade was a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Paula Green sold 1,084 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $34,774.72. Following the completion of the sale, the senior vice president directly owned 142,187 shares of the company’s stock, valued at approximately $4,561,358.96. This trade represents a 0.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 119,110 shares of company stock worth $3,783,237 over the last quarter. Insiders own 3.01% of the company’s stock.

Twist Bioscience Price Performance

Shares of TWST stock opened at $32.13 on Thursday. The company has a market capitalization of $1.96 billion, a P/E ratio of -24.53 and a beta of 2.24. The company’s 50-day simple moving average is $30.90 and its two-hundred day simple moving average is $31.14. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $55.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The company had revenue of $99.01 million for the quarter, compared to the consensus estimate of $97.40 million. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. Stephens started coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Evercore ISI dropped their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Finally, Barclays increased their price target on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and an average price target of $44.88.

Check Out Our Latest Stock Analysis on Twist Bioscience

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Articles

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).